EP1545596A4 - Use of histamine h4 receptor modulators for the treatment of allergy and asthma - Google Patents

Use of histamine h4 receptor modulators for the treatment of allergy and asthma

Info

Publication number
EP1545596A4
EP1545596A4 EP03794649A EP03794649A EP1545596A4 EP 1545596 A4 EP1545596 A4 EP 1545596A4 EP 03794649 A EP03794649 A EP 03794649A EP 03794649 A EP03794649 A EP 03794649A EP 1545596 A4 EP1545596 A4 EP 1545596A4
Authority
EP
European Patent Office
Prior art keywords
histamine
allergy
asthma
treatment
receptor modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03794649A
Other languages
German (de)
French (fr)
Other versions
EP1545596A2 (en
Inventor
Pragnya J Desai
Paul J Dunford
Claudia L Hofstra
Lars Karlsson
Wai-Ping Leung
Ping Ling
Robin L Thurmond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of EP1545596A2 publication Critical patent/EP1545596A2/en
Publication of EP1545596A4 publication Critical patent/EP1545596A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP03794649A 2002-09-06 2003-09-05 Use of histamine h4 receptor modulators for the treatment of allergy and asthma Withdrawn EP1545596A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40873602P 2002-09-06 2002-09-06
US408736P 2002-09-06
PCT/US2003/027943 WO2004021999A2 (en) 2002-09-06 2003-09-05 Use of histamine h4 receptor modulators for the treatment of allergy and asthma

Publications (2)

Publication Number Publication Date
EP1545596A2 EP1545596A2 (en) 2005-06-29
EP1545596A4 true EP1545596A4 (en) 2005-12-28

Family

ID=31978667

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03794649A Withdrawn EP1545596A4 (en) 2002-09-06 2003-09-05 Use of histamine h4 receptor modulators for the treatment of allergy and asthma

Country Status (6)

Country Link
EP (1) EP1545596A4 (en)
JP (1) JP2006510590A (en)
AU (1) AU2003265961A1 (en)
CA (1) CA2497788A1 (en)
MX (1) MXPA05002577A (en)
WO (1) WO2004021999A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1671972A1 (en) * 2004-11-24 2006-06-21 Pfizer Limited Octahydropyrrolo[3,4-c]pyrrole derivatives
JP2008520644A (en) * 2004-11-24 2008-06-19 ファイザー・インク Octahydropyrrolo [3,4-c] pyrrole derivative
EP2001480A4 (en) 2006-03-31 2011-06-15 Abbott Lab Indazole compounds
JP5306818B2 (en) * 2006-10-18 2013-10-02 武田薬品工業株式会社 Fused heterocyclic compounds
KR100954138B1 (en) * 2007-12-31 2010-04-20 부산대학교 산학협력단 An agent comprising adipose tissue?derived stem cells as effective ingredient for prevention and treatment of allergic rhinitis or asthma
EP2201982A1 (en) * 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
JP2012102017A (en) * 2009-03-03 2012-05-31 Astellas Pharma Inc Indole compound

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072548A2 (en) * 2001-03-09 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds and their use as histamine h4 ligands.
WO2003057919A2 (en) * 2001-12-21 2003-07-17 Ortho-Mcneil Pharmaceutical, Inc. The use of histamine h4 receptor antagonist for the treatment of inflammatory response
WO2004022061A1 (en) * 2002-09-06 2004-03-18 Janssen Pharmaceutica, N.V. Use of indolyl derivatives for the manufacture of a medicament for the treatment allergic rhinitis
WO2004022060A2 (en) * 2002-09-06 2004-03-18 Janssen Pharmaceutica, N.V. (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001259513A1 (en) * 2000-05-05 2001-11-20 Wyeth Human histamine h4 receptor
WO2001092485A1 (en) * 2000-05-31 2001-12-06 Ortho-Mcneil Pharmaceutical, Inc. DNAs ENCODING MAMMALIAN HISTAMINE RECEPTOR OF THE H4 SUBTYPE
GB0101223D0 (en) * 2001-01-17 2001-02-28 Pfizer Ltd Histamine receptor antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072548A2 (en) * 2001-03-09 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds and their use as histamine h4 ligands.
WO2003057919A2 (en) * 2001-12-21 2003-07-17 Ortho-Mcneil Pharmaceutical, Inc. The use of histamine h4 receptor antagonist for the treatment of inflammatory response
WO2004022061A1 (en) * 2002-09-06 2004-03-18 Janssen Pharmaceutica, N.V. Use of indolyl derivatives for the manufacture of a medicament for the treatment allergic rhinitis
WO2004022060A2 (en) * 2002-09-06 2004-03-18 Janssen Pharmaceutica, N.V. (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HOFSTRA C L ET AL: "Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells.", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 305, no. 3, June 2003 (2003-06-01), pages 1212 - 1221, XP002352480, ISSN: 0022-3565 *
LIU C ET AL: "Comparison of human, mouse, rat and guinea pig histamine H4 receptors reveals substantial pharmacological species variation", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, vol. 299, no. 1, 2001, pages 121 - 130, XP009013631, ISSN: 0022-3565 *
O'REILLY M ET AL: "Identification of a histamine H4 receptor of human eosinophils - role in eosinophil chemotaxis", JOURNAL OF RECEPTOR AND SIGNAL TRANSDUCTION RESEARCH, MARCEL DEKKER, NEW YORK, NY, US, vol. 22, no. 1-4, February 2002 (2002-02-01), pages 431 - 448, XP009047851, ISSN: 1079-9893 *
THURMOND R L ET AL: "A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 309, no. 1, 1 April 2004 (2004-04-01), pages 404 - 413, XP002352481, ISSN: 0022-3565 *

Also Published As

Publication number Publication date
WO2004021999A3 (en) 2004-10-07
WO2004021999A2 (en) 2004-03-18
EP1545596A2 (en) 2005-06-29
CA2497788A1 (en) 2004-03-18
AU2003265961A1 (en) 2004-03-29
JP2006510590A (en) 2006-03-30
MXPA05002577A (en) 2005-09-20

Similar Documents

Publication Publication Date Title
HK1205748A1 (en) Therapeutic epitopes and uses thereof
AU2003256253A8 (en) Aerosol for medical treatment and methods
EP1509279A4 (en) Device and method for the treatment of cardiac disorders
HK1079203A1 (en) Substituted amine derivatives and methods of use in the treatment of angiogenesis related disorders
EP1576033A4 (en) Process for producing polysiloxanes and use of the same
IL164703A0 (en) ImidazoÄ1,2-AÜpyrazin-8-ylamines method of making and method of use thereof
AU2003281736A8 (en) Electrodes and related devices
AU2003259717A8 (en) Modulators of rabggt and methods of use thereof
HK1203216A1 (en) Materials and methods for treating disorders of the ear
HUP0401808A3 (en) Dosage forms, devices and methods of treatment
GB2389410B (en) Lighter and method of use
EP1476150A4 (en) Carboxyfullerenes and methods of use thereof
AU2003286737A8 (en) Apparatuses and methods for the manufacture and placement of truss assemblies
GB2394672B (en) Applicator and/or Stimulator Device
EP1545507A4 (en) Activated checkpoint therapy and methods of use thereof
EP1518925A4 (en) Crystal of glucokinase protein, and method for drug design using the crystal
EP1545596A4 (en) Use of histamine h4 receptor modulators for the treatment of allergy and asthma
GB0207410D0 (en) Compounds and their therapeutic use
AU2001249262A1 (en) Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof
AU2003262229A1 (en) Preventive and/or therapeutic drugs for asthma
AU2003250831A1 (en) Use of hec1 antagonists in the treatment of proliferative disorders and cancer
AU2003223094A1 (en) Hand held device for inhalation therapy and method of use thereof
AU2003259689A1 (en) 3-imino-2-indolones for the treatment of depression and/or anxiety
GB0207409D0 (en) Benzofuran-2H-3-one compounds and their therapeutic use
GB0205395D0 (en) Materials and methods relating to the treatment of lymphoma

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050405

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20051115

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: 7G 01N 33/53 B

Ipc: 7C 07K 16/00 B

Ipc: 7A 61K 47/00 B

Ipc: 7A 61K 39/00 A

RIN1 Information on inventor provided before grant (corrected)

Inventor name: THURMOND, ROBIN, L.

Inventor name: LING, PING

Inventor name: LEUNG, WAI-PING

Inventor name: KARLSSON, LARS

Inventor name: HOFSTRA, CLAUDIA, L.

Inventor name: DUNFORD, PAUL, J.

Inventor name: DESAI, PRAGNYA, J.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20070305